Cellular/Molecular

Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection Neurons

Mikael Andersson,1 Alessandro Usiello,1,5 Anders Borgkvist,1 Laura Pozzi,1 Cecilia Dominguez,1 Allen A. Fienberg,3,4 Per Svenningsson,1 Bertil B. Fredholm,2 Emilianna Borrelli,2 Paul Greengard,4 and Gilberto Fisone1,4

1Department of Neuroscience and 2Department of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden, 3Intra-Cellular Therapies Inc., New York, New York 10032, 4Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10021, and 5Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université Louis Pasteur, 67404 Illkirch Cedex, Strasbourg, France

Herbal cannabis, smoked in the form of marihuana or hashish, is the most common illicit drug consumed in the Western world. In the brain, cannabinoids interact with neuronal CB1 receptors, thereby producing a marked reduction of motor activity. Here, we report that the motor depressant effect produced by the cannabinoid receptor agonist (−)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]trans-4-(3-hydroxypropyl)cyclohexanol (CP55,940) is attenuated by genetic inactivation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), which is abundantly expressed in the medium spiny neurons of the striatum. Point mutation of Thr34, the protein kinase A (PKA) phosphorylation site of DARPP-32, is which is characterized by rigid immobility, or catalepsy, and decreased locomotion, occurs via activation of neuronal cannabinoid receptors belonging to the CB1 subtype (Ledent et al., 1999).

Key words: basal ganglia; movement; CB1 receptor; adenosine; D2; knock-out

Introduction

Cannabinoids, such as Δ9-tetrahydrocannabinol, the major psychoactive ingredient of marihuana and hashish, are known to produce a marked depression of motor activity. This effect, which is characterized by rigid immobility, or catalepsy, and decreased locomotion, occurs via activation of neuronal cannabinoid receptors belonging to the CB1 subtype (Ledent et al., 1999). CB1 receptors are abundantly expressed in the basal ganglia (Herkenham et al., 1990), a group of subcortical structures that regulate motor behavior. In the striatum, the major component of the basal ganglia, CB1 receptors regulate neurotransmission in various manners. For instance, WIN-55,212–2 (R-(-)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate), a CB1 receptor agonist, inhibits the release of glutamate from corticostriatal synapses, thereby reducing excitatory postsynaptic currents evoked on medium-sized spiny neurons (Gerde and Lovinger, 2001). CB1 receptor agonists are also able to decrease GABA release from recurrent axon collaterals of medium spiny neurons, thereby reducing inhibitory synaptic transmission intrinsically to the striatum (Szabo et al., 1998). The endocannabinoid system has been shown to exert both negative and positive control on striatal dopamine D2 receptor activation. Activation of dopamine D2 receptors results in increased levels of the endocannabinoid anandamide, which acts as a negative feedback by reducing the motor stimulant effect of quinpirole, a dopamine D2 receptor agonist (Giuffrida et al., 1999; Beltramo et al., 2000). Recently, however, anandamide has been proposed to act as a downstream effector that mediates the...
inhibition produced by dopamine D₃ receptors on GABA transmission (Centonze et al., 2004). These various and contrasting actions of cannabinoids led us to analyze their overall effects on striatal medium spiny neurons in an attempt to clarify specific molecular changes involved in the generation of CB1 receptor-mediated motor depression.

The dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) (Walaas et al., 1983) is highly and specifically expressed in striatal projection neurons (Walaas and Greengard, 1984; Ouimet et al., 1998), in which it acts as a modulator of the cAMP pathway. Phosphorylation catalyzed by protein kinase A (PKA) at Thr34 converts DARPP-32 into an inhibitor of protein phosphatase-1 (Hemmings et al., 1984). This, in turn, prevents dephosphorylation of downstream target proteins, thereby amplifying the effects produced by activation of the cAMP/PKA cascade (Greengard, 2001). DARPP-32 is implicated in the generation of motor responses produced by various classes of drugs that activate or inhibit the cAMP/PKA pathway in striatal medium spiny neurons. Thus, changes in DARPP-32 phosphorylation are involved in the psychomotor effects produced by amphetamine (Fienberg et al., 1998), caffeine (Lindskog et al., 2002), and anti-psychotics (Fienberg et al., 1998).

In this study, we examined the effects produced by activation of CB1 receptors on DARPP-32 phosphorylation and the possible involvement of DARPP-32 in the psychomotor effects of a CB1 receptor agonist. Our results indicate that phosphorylation of DARPP-32 on Thr34 is necessary for a full behavioral response to cannabinoids. They also suggest a molecular mechanism accounting for the motor depressant effect of cannabinoids, which involves suppression of dopamine D₃ receptor-mediated inhibition of DARPP-32 phosphorylation in striatal projection neurons.

Materials and Methods

Audomals. Male C57BL/6 mice (20–30 g) were obtained from M&M (By, Denmark). Wild-type and DARPP-32 knock-out mice (Fienberg et al., 1998) were generated from the offspring of DARPP-32 normal × DARPP-32 normal and DARPP-32 normal × DARPP-32 mutant mating pairs. These mating pairs were obtained from heterozygous mice, which were backcrossed for at least 20 generations on a C57BL/6 background. DARPP-32 normal × DARPP-32 normal and DARPP-32 normal × DARPP-32 mutant mating was performed separately for no more than two generations. Mice bearing a mutation in which Thr34 or Thr75 were replaced by a nonphosphorylatable Ala (Thr34 → Ala and Thr75 → Ala mutant mice, respectively) (Svenningsson et al., 2003) were obtained from heterozygous animals, bred for five generations on a C57BL/6 background.

In a first series of experiments, we examined the ability of CB1 receptors to regulate DARPP-32. The activity of DARPP-32 is controlled by phosphorylation at multiple sites, including two critical threonyl residues located in positions 34 and 75. Phosphorylation of Thr34 is catalyzed by PKA and converts DARPP-32 into an inhibitor of PKA (Bibb et al., 1999). Systemic administration of CP55,940 increased DARPP-32 phosphorylation at the PKA site, Thr34 (Fig. 1 a–c), without producing any consistent modification of Thr75 phosphorylation (data not shown). Half-maximal stimulation of Thr34 phosphorylation was observed at 0.3 mg/kg CP55,940, and maximal stimulation was observed at 0.5 mg/kg (Fig. 1 a). The level of phosphoThr34-DARPP-32 reached a peak 1 h after CP55,940 administration and returned to near baseline levels after 2 h (Fig. 1 b). The selective CB1 receptor antagonist, SR141716A, prevented the increase in phosphoThr34-DARPP-32 induced by CP55,940, confirming the specific involvement of CB1 receptors in the regulation of DARPP-32 phosphorylation (Fig. 1 c). SR141716A did not produce any effect on DARPP-32 phosphorylation when administered alone. This observation is in agreement with previous work showing that SR141716A does not affect motor activity (Rinaldi-Carmona et al., 1994) and supports the idea that, under normal conditions, the level of activation of CB1 receptors is negligible.

We also examined the ability of endogenous cannabinoids (anandamide and 2-arachidonoylglycerol) to regulate DARPP-32 phosphorylation. We found that the effect of CP55,940 on DARPP-32 phosphorylation was mimicked by AM404, an inhibitor of anandamide and 2-arachidonoylglycerol receptor (Beltramo and Piomelli, 2000) (Fig.
1d,e). The AM404-induced increase in phosphoThr34-DARPP-32 was blocked by SR141716A (Fig. 1f). Thus, activation of CB1 receptors, achieved either by administering a synthetic agonist or by elevating the levels of endogenous cannabinoids, resulted in increased phosphorylation of DARPP-32 at Thr34, the PKA phosphorylation site.

**PhosphoThr34-DARPP-32 is involved in CB1 receptor-mediated catalepsy**

Based on the results from biochemical studies, we investigated whether DARPP-32 is required for the generation of the behavioral response to activation of CB1 receptors. As shown in Figure 2a, CP55,940 (a cannabinoid receptor agonist) induced a cataleptic effect in wild-type mice, which was maximal 2 h after systemic administration. We found that the motor depressant effect of CP55,940 was strongly attenuated in DARPP-32 null mice (Fig. 2a). To evaluate the involvement of PKA-catalyzed phosphorylation of DARPP-32 at Thr34 in the psychomotor effects produced by activation of CB1 receptors, we tested the ability of CP55,940 to elicit catalepsy in Thr34 → Ala mutant mice. The results indicated that, in these animals, CP55,940-induced catalepsy was significantly attenuated (Fig. 2b). Moreover, we found that the cataleptic response produced by the CB1 receptor agonist in Thr75 → Ala mutant mice was indistinguishable from that elicited in wild-type littermates (Fig. 2c).

**Intact dopamine D2 and adenosine A2A receptor transmission are required for full cannabinoid action**

Previous evidence indicates that, in the striatum, blockade of dopamine D2 receptors increases PKA-dependent phosphorylation of DARPP-32 (Svenningsson et al., 2000). In view of the ability of CB1 receptors to antagonize D2 receptor-mediated responses (Giuffrida et al., 1999; Beltramino et al., 2000), we tested the possibility that the stimulation of Thr34 phosphorylation and the motor depression caused by activation of CB1 receptors require intact dopamine D2 receptor transmission. We found that, in D2 receptor-deficient mice, the increase in phosphoThr34-DARPP-32 produced by CP55,940 was markedly reduced (Fig. 3a). Neither genetic inactivation of dopamine D2 receptors nor treatment with CP55,940 modified the immunoreactivity corresponding to total (i.e., phosphorylated plus dephosphorylated) DARPP-32 (data not shown). In agreement with the biochemical data and further supporting the idea of an involvement of phosphorylation of Thr34 of DARPP-32 in the psychomotor effect of cannabinoids, we also found that, in D2 receptor knock-out mice, the cataleptic response to CP55,940 was diminished (Fig. 3b).

Dopamine D2 receptors are coexpressed with adenosine A2A receptors in a large population of striatal medium spiny neurons. In these cells, the state of phosphorylation of DARPP-32 at Thr34 reflects a balance between activation of adenosine A2A receptors, which stimulate PKA by increasing the production of cAMP, and activation of dopamine D2 receptors, which reduce PKA activity via inhibition of the production of cAMP. Thus, increases in Thr34 phosphorylation produced by blockade of dopamine D2 receptors are dependent on intact adenosine A2A receptor transmission (Svenningsson et al., 2000). Based on these considerations and taking into account the involvement of dopamine D2 receptors in cannabinoid-mediated responses (compare Fig. 3), we examined the possible role of A2A receptors in the effects of CP55,940. We found that the ability of the CB1 receptor agonist to stimulate DARPP-32 phosphorylation at Thr34 was strongly reduced in A2A receptor-null mice (Fig. 4a). Moreover, in the same strain of mice, the cataleptic response to CP55,940 was also attenuated (Fig. 4b). We also examined the effect of pharmacological blockade of adenosine A2A receptors on CP55,940-induced phosphorylation of DARPP-32 and motor depression. We found that administration of the selective A2A receptor antagonist, KW6002 (3 mg/kg), reduced the ability of CP55,940 to increase Thr34 phosphorylation (Fig. 4c). KW6002 was also able to attenuate the catalepsy produced by administration of the CB1 receptor agonist (Fig. 4d), thereby confirming the importance of...
phosphorylation at Thr34 is somewhat unexpected, because CB1 receptors appear to be "represent means (of that determined in wild-type mice after vehicle administration. Data represent means ± SEM (n = 6–10). The effect of CP55,940 was significantly reduced in DARPP-32 knock-out mice (F_{1,24} = 4.40; p < 0.05) and Thr34 → Ala mice (F_{1,24} = 4.42; p < 0.05; repeated-measures ANOVA)."

**Discussion**

One finding of this study is that activation of CB1 receptors, achieved by systemic administration of CB1 receptor agonists or by enhancing the levels of endogenous cannabinoids, resulted in increased phosphorylation of DARPP-32 at the PKA site, Thr34, and that this phosphorylation is required for the generation of a full behavioral response to cannabinoids. Another conclusion stemming from this study is that the reduction in motor activity produced by stimulation of CB1 receptors appears to be mediated by activation of the cAMP/PKA pathway in a specific group of striatal projection neurons, which express dopamine D2 and adenosine A2A receptors.

The ability of CP55,940 and AM404 to stimulate DARPP-32 phosphorylation at Thr34 is somewhat unexpected, because CB1 receptors are known to inhibit the activity of adenyl cyclase and reduce the levels of cAMP via coupling to G{i/o}-proteins (Howlett et al., 1986; Bidaut-Russell et al., 1990) (but see Maneuf and Brothcie, 1997). This notion, however, rests on studies performed in isolated systems such as cultured cells, brain membranes, or tissue slices, which do not take into account the effects of systemic activation of CB1 receptors under normal physiological circumstances.

In this regard, it should be noted that stimulation of cAMP accumulation has been shown to occur in striatal neurons after coactivation of CB1 and dopamine D2 receptors (Glass and Felder, 1997). The mechanism underlying this phenomenon is not clear, but recent evidence shows that heterodimerization with dopamine D2 receptors is associated with a shift of CB1 receptor signaling from inhibition to stimulation of adenyl cyclase (Kearn et al., 2005). It is therefore possible that the increase in PKA-catalyzed phosphorylation of DARPP-32 produced by cannabinoids in intact animals is a result of stimulation of postsynaptic CB1 receptors in the presence of tonic activation of dopamine D2 receptors. This explanation is in line with the diminished effect of CP55,940 on DARPP-32 phosphorylation observed in dopamine D2 receptor knock-out mice and is supported by studies reporting the presence of CB1 receptors on the dendrites of striatal medium spiny neurons (Rodriguez et al., 2001).

Several studies have demonstrated that activation of glutamate receptors results in dephosphorylation of DARPP-32 (Svenningsson et al., 2004). Thus, another possible mechanism responsible for the increase in phosphoThr34-DARPP-32 produced by cannabinoid receptor agonists could involve reduction of glutamate release (Gerdeman and Lovinger, 2001) and suppression of DARPP-32 dephosphorylation. Indeed, CB1 receptors are, in large part, expressed presynaptically, and cannabinoids have been proposed to act as inhibitory retrograde messengers at glutamatergic corticostriatal synapses (Gerdeman et al., 2002).

Our data show a comparable attenuation of the ability of CP55,940 to induce catalepsy in DARPP-32 knock-out mice and Thr34 → Ala DARPP-32 mutant mice. However, the data presented in Figure 2 also show a different sensitivity to the CB1 receptor agonist among the groups of wild-type animals used in the three sets of experiments. Thus, the catalepsy induced by CP55,940 in the wild-type group used to evaluate the response of DARPP-32 knock-out mice (compare Fig. 2a) is lower than that observed in the wild-type groups used to determine the effects of mutation of Thr34 or Thr75 (compare Fig. 2b,c). This difference is most likely attributable to the genetic background of the strains of mice used in these studies. DARPP-32 knock-out and corresponding wild-type mice were backcrossed for several generations on a C57BL/6 background. In contrast, Thr34 → Ala DARPP-32 mutant mice, Thr75 → Ala DARPP-32 mutant mice, and wild-type littermates were generated from mating pairs bred only for one backcross for several generations on a C57BL/6 background.
of dopamine D2 receptors are strongly attenuated in the absence that biochemical and behavioral responses produced by blockade and adenosine A2A receptors. In particular, it has been found that the ability of CP55,940 to stimulate Thr34 phosphorylation and Vanderhaeghen, 1993). The present findings, which show pressed in striatopallidal neurons (Fink et al., 1992; Schiffmann receptors (Svenningsson et al., 2000), which are selectively ex-

The increase in DARPP-32 phosphorylation at Thr34 pro-
duced by cocaine and amphetamine is mediated via activation of dopamine D1 receptors, which are positively coupled to cAMP production and preferentially expressed in striatongrial neurons (Gerfen, 1992). Indeed, administration of the dopamine D1 receptor antagonist SCH23390 [8-chloro-2,3,4,5-tetrahydro-3–5-

Adenosine A2A receptor activation is required for the biochemical and behavioral effects of CP55,940. a, b, Wild-type (WT; CD1 background) or adenosine A2A receptor knock-out (A2A KO) mice were treated intraperitoneally with vehicle (filled bars) or CP55,940 (0.5 mg/kg, i.p.; open bars). c, d, C57BL/6 mice were treated intraperitoneally with vehicle, CP55,940, KW6002, or a combination of the two drugs (injected at the same time). Mice were killed 60 min after vehicle or drug administration, and the striatal levels of phosphorylated DARPP-32 were determined as described in Materials and Methods. The top panels show representative gels; the bottom panels show summaries of experiments. The amount of phosphorylated DARPP-32 is expressed as a percentage of that determined in wild-type mice after vehicle administration. Data represent means ± SEM (n = 8–11). The effect of CP55,940 was significantly reduced in A2A receptor knock-out mice (F(1,3,13) = 51.45; p < 0.01), and treatment with KW6002 significantly reduced the effect of CP55,940 (F(1,3,13) = 5.006; p < 0.05; two-way ANOVA). c, d, Catalepsy was determined 15, 30, 60, 120, and 180 min after administration of CP55,940 (0.5 mg/kg) to wild-type or A2A receptor knock-out mice (b) or administration of CP55,940, KW6002, or a combination of the two drugs to C57BL/6 mice (d). Data represent means ± SEM (n = 6–15). The effect of CP55,940 was significantly reduced in A2A receptor knock-out mice (F(1,20) = 4.60; p < 0.05); treatment with KW6002 significantly reduced the effect of CP55,940 (F(1,20) = 9.015; p < 0.05; repeated-measures ANOVA).

Figure 4. Adenosine A2A receptor activation is required for the biochemical and behavioral effects of CP55,940. a, b, Wild-type (WT; CD1 background) or adenosine A2A receptor knock-out (A2A KO) mice were treated intraperitoneally with vehicle (filled bars) or CP55,940 (0.5 mg/kg, i.p.; open bars). c, d, C57BL/6 mice were treated intraperitoneally with vehicle, CP55,940, KW6002, or a combination of the two drugs (injected at the same time). Mice were killed 60 min after vehicle or drug administration, and the striatal levels of phosphorylated DARPP-32 were determined as described in Materials and Methods. The top panels show representative gels; the bottom panels show summaries of experiments. The amount of phosphorylated DARPP-32 is expressed as a percentage of that determined in wild-type mice after vehicle administration. Data represent means ± SEM (n = 8–11). The effect of CP55,940 was significantly reduced in A2A receptor knock-out mice (F(1,3,13) = 51.45; p < 0.01), and treatment with KW6002 significantly reduced the effect of CP55,940 (F(1,3,13) = 5.006; p < 0.05; two-way ANOVA). c, d, Catalepsy was determined 15, 30, 60, 120, and 180 min after administration of CP55,940 (0.5 mg/kg) to wild-type or A2A receptor knock-out mice (b) or administration of CP55,940, KW6002, or a combination of the two drugs to C57BL/6 mice (d). Data represent means ± SEM (n = 6–15). The effect of CP55,940 was significantly reduced in A2A receptor knock-out mice (F(1,20) = 4.60; p < 0.05); treatment with KW6002 significantly reduced the effect of CP55,940 (F(1,20) = 9.015; p < 0.05; repeated-measures ANOVA).

This study shows that the ability of CP55,940 to phosphorylate DARPP-32 and produce catalepsy requires dopamine D2 recep-
tors. Based on previous data indicating the existence of a negative control exerted by cannabinoids on dopamine D2 receptor trans-
mission (Giuffrida et al., 1999; Beltramo et al., 2000), we propose that activation of CB1 receptors increases Thr34 phosphorylation by antagonizing the inhibition exerted by dopamine D2 receptors on the cAMP/PKA cascade. Considerable evidence indicates the existence of a complex interaction between dopamine D2 recep-
tors and adenosine A2A receptors. In particular, it has been found that biochemical and behavioral responses produced by blockade of dopamine D2 receptors are strongly attenuated in the absence of adenosine A2A receptors (Svenningsson et al., 2000; Chen et al., 2001), which maintain a normal level of cAMP production in striatopallidal neurons. In light of these observations, our findings that biochemical and behavioral effects of CP55,940 are reduced in A2A receptor knock-out mice further strengthens the idea that CB1 receptors act by counteracting dopamine D2 receptor transmission. Such a counteraction would result in disinhibition/facilitation of adenosine A2A receptor–dependent activation of the cAMP/PKA/DARPP-32 cascade in the striatal projection neurons of the indirect pathway. Thus, we propose that CB1 receptors act on striatopallidal neurons as follows: (1) by reducing dopamine D2 receptor transmission, (2) by disinhibiting A2A receptor–dependent activation of PKA, and (3) by phosphorylating DARPP-32 at Thr34.

Dopamine D2 receptors and adenosine A2A receptors exert opposite effects on striatopallidal neurons and on motor function. However, our results show that their genetic inactivation results in a similar attenuation of the biochemical and behavioral...
effects of CP55,940. This paradox can be explained by assuming that CB1 receptors act by antagonizing D2 receptor transmission and promoting A2A receptor transmission. Such opposite regulations are equally prevented in knock-out mice. Indeed, dopamine D1 and adenosine A2A receptor-null mice show reduced responses to both agonists and antagonists (Boulay et al., 1999, 2000; Ledent et al., 1997).

Previous studies indicated that the psychostimulant effect of caffeine, an adenosine A2A receptor antagonist, involves phosphorylation of DARP-32 at Thr75 (Lindsgård et al., 2002). This change in DARP-32 phosphorylation resulted in reduced PKA activity and suppression of protein phosphorylation in striatopallidal neurons. Remarkably, the present results show that cannabinoids produce their motor depressant effect by an opposite action on protein phosphorylation in the same population of projection neurons. Thus, activation of CB1 receptors leads to stimulation of DARP-32 phosphorylation at Thr34, reduction of PP-1 activity, and increased phosphorylation of downstream target proteins involved in the regulation of the state of excitability of striatopallidal neurons. These downstream target phosphoproteins remain to be identified.

References

Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 15:285–320.


